BioVaxys Technology (5LB0) Stock Price & Analysis

0 Followers

5LB0 Stock Chart & Stats

€0.03€0.00(0.00%)

At close: Nov 13 5:30 PM GMT+1

Day’s Range: EUR 0.03 - EUR 0.03
52-Week Range: EUR 0.02 - EUR 0.18
Previous Close: EUR 0.03
Volume: N/A
Average Volume (3M): 0
Market Cap: EUR 1.30M
Enterprise Value: EUR 5.96M
Total Cash (Recent Filing): EUR 4,080
Total Debt (Recent Filing): EUR 133.72K
Price to Earnings (P/E): ―
Beta: 0.14
Next Earnings: Apr 01, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

BioVaxys Technology News

BioVaxys Updates Market on Cease Trade Order and Delayed Filings

BioVaxys Technology ( ($TSE:BIOV) ) just unveiled an announcement. BioVaxys Technology Corp. reported that it remains under a management cease trade order imposed by the British Columbia Securities Commission after

7M agoBVAXF 5LB0

BioVaxys Updates on Filing Delays as Executives Face Trading Restrictions

BioVaxys Technology ( ($TSE:BIOV) ) just unveiled an announcement. BioVaxys Technology Corp., a clinical-stage biopharmaceutical company focused on immunotherapies for cancer, infectious disease, food allergy desensitization, and other immune disorders,

7M agoBVAXF 5LB0

BioVaxys Extends Financial Filing Delay Under Management Cease Trade Order

BioVaxys Technology ( ($TSE:BIOV) ) has provided an update. BioVaxys Technology Corp. reported that it remains under a management cease trade order after failing to file its audited annual financial

8M agoBVAXF 5LB0

BioVaxys and Adiverna Team Up on AI-Driven mRNA Vaccines for Pets

An update from BioVaxys Technology ( ($TSE:BIOV) ) is now available. BioVaxys Technology and Adiverna have entered a research collaboration to develop mRNA-based vaccines for companion animals, initially targeting rabies,

8M agoBVAXF 5LB0

BioVaxys Applies for Management Cease Trade Order After Audit-Related Filing Delay

An update from BioVaxys Technology ( ($TSE:BIOV) ) is now available. BioVaxys Technology Corp., a Vancouver-based clinical-stage biopharmaceutical company, develops immunotherapies built on its DPX immune-educating platform and HapTenix tumor

8M agoBVAXF 5LB0

BioVaxys Cancer Vaccine Combo Shows Durable Responses in Recurrent Ovarian Cancer Trial

BioVaxys Technology ( ($TSE:BIOV) ) just unveiled an update. BioVaxys reported positive preliminary data from its investigator-initiated Phase 1b/2 PESCO trial evaluating a combination of its MVP-S cancer vaccine with

9M agoBVAXF 5LB0

BioVaxys Advances DPX Vaccine Platform With New Collaborations and Positive Trial Data

BioVaxys Technology ( ($TSE:BIOV) ) has provided an announcement. BioVaxys Technology is advancing a series of collaborations and non-dilutive funding initiatives in early 2026, including participation in a U.S. BARDA

10M agoBVAXF 5LB0

BioVaxys Posts Strong Phase 1 Data for DPX Cancer Vaccines in Bladder Cancer

BioVaxys Technology ( ($TSE:BIOV) ) just unveiled an announcement. BioVaxys reported highly promising Phase 1 clinical data showing that its DPX-formulated cancer vaccines MVP-S and DPX-SurMAGE were well tolerated and

10M agoBVAXF 5LB0

BioVaxys Sharpens DPX Vaccine Strategy With New Leadership and Positive Breast Cancer Data

BioVaxys Technology ( ($TSE:BIOV) ) just unveiled an announcement. BioVaxys’ 2025 corporate review highlights the integration of the DPX platform into its operations and a strategic shift toward organic growth

10M agoBVAXF 5LB0

BioVaxys Reports Promising Phase 1 Results for Breast Cancer Treatment MVP-S

An announcement from BioVaxys Technology ( ($TSE:BIOV) ) is now available. BioVaxys Technology Corp. has reported positive phase 1 clinical study results for its innovative candidate MVP-S in combination with

11M agoBVAXF 5LB0

5LB0 FAQ

What was BioVaxys Technology’s price range in the past 12 months?

BioVaxys Technology lowest stock price was €0.02 and its highest was €0.18 in the past 12 months.

What is BioVaxys Technology’s market cap?

BioVaxys Technology’s market cap is €1.30M.

When is BioVaxys Technology’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were BioVaxys Technology’s earnings last quarter?

BioVaxys Technology released its earnings results on Oct 02, 2025. The company reported -€0.02 earnings per share for the quarter.

Is BioVaxys Technology overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does BioVaxys Technology pay dividends?

BioVaxys Technology does not currently pay dividends.

What is BioVaxys Technology’s EPS estimate?

BioVaxys Technology’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BioVaxys Technology have?

BioVaxys Technology has 44,094,670 shares outstanding.

What happened to BioVaxys Technology’s price movement after its last earnings report?

BioVaxys Technology reported an EPS of -€0.02 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of BioVaxys Technology?

Currently, no hedge funds are holding shares in DE:5LB0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

BioVaxys Technology

BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SARS-CoV-2, and BVX-0918A, an experimental haptenized tumor cell vaccine targeting ovarian cancer. Additionally, BioVaxys offers CoviDTH, an immunodiagnostic tool to detect immune system activity in SARS-CoV-2-exposed patients. Further initiatives encompass Papilocare, aimed at HPV-dependent cervical lesions, along with BVX-0918C for cervical cancer, the HPV viral vaccine BVX-0204, and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys has established strategic collaborations, such as a bioproduction agreement with WuXi Biologics Limited to manufacture SARS-CoV-2 s-proteins crucial for BVX-0320 and CoviDTH. It also holds a research partnership with The Ohio State University, Wexner School of Medicine, focusing on BVX-0320, and has engaged Bioanalytical Systems, Inc. for preclinical toxicology evaluations of its CoviDTH immunodiagnostic. The company is headquartered in Vancouver, Canada.

BioVaxys Technology (5LB0) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	9	1	9
Technical Analysis	3	1	3
Moving Averages	6	0	6

Technical Analysis >

Similar Stocks

Stocks similar to DE:5LB0
Company	Price & Change	Follow
TSE:ARCHArch Biopartners
TSE:MDNAMedicenna Therapeutics Corp
TSE:BCTBriaCell Therapeutics
TSE:VXLVaxil Bio
TSE:DTCDefence Therapeutics

Compare DE:5LB0 Stocks >

Ownership Overview

8.08% Insiders
91.92% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

5LB0 Stock Chart & Stats

BioVaxys Technology News

BioVaxys Updates Market on Cease Trade Order and Delayed Filings

BioVaxys Updates on Filing Delays as Executives Face Trading Restrictions

BioVaxys Extends Financial Filing Delay Under Management Cease Trade Order

BioVaxys and Adiverna Team Up on AI-Driven mRNA Vaccines for Pets

BioVaxys Applies for Management Cease Trade Order After Audit-Related Filing Delay

BioVaxys Cancer Vaccine Combo Shows Durable Responses in Recurrent Ovarian Cancer Trial

BioVaxys Advances DPX Vaccine Platform With New Collaborations and Positive Trial Data

BioVaxys Posts Strong Phase 1 Data for DPX Cancer Vaccines in Bladder Cancer

BioVaxys Sharpens DPX Vaccine Strategy With New Leadership and Positive Breast Cancer Data

BioVaxys Reports Promising Phase 1 Results for Breast Cancer Treatment MVP-S

5LB0 FAQ

Company Description

BioVaxys Technology

BioVaxys Technology (5LB0) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium